Subject Index for Bibliography regarding Studies Using WHHL Rabbits

Click paper numbers, then you can find the paper and access the abstract or full paper.

I. Atherosclerosis

I-1. Histopathological Studies

1) Plaque stability: (325) (444) (480) (482) (483) (495) (506) (509) (536) (540) (561) (562) (598) (600) (605) (610) (623) (625) (626) (629) (634) (708) (740)
2) Fine structure: (18) (54) (60) (62) (64) (133) (165) (226) (264) (265) (425) (481) (643)
3) Early lesion or initiation: (63) (217) (265) (293) (306) (331) (381) (462) (467) (488) (489) (491) (527) (566) (645) (629) (634) (708) (733)
4) Plaque composition: (293) (306) (325) (410) (412) (441) (444) (445) (446) (476) (480) (482) (487) (491) (505) (506) (509) (536) (566) (569) (605) (620) (623) (625) (626) (627) (629) (634) (636) (699) (708) (709) (733)
5) Macrophage (45) (47) (63) (64) (82) (84) (150) (153) (211) (217) (222) (226) (237) (285) (288) (296) (306) (325) (331) (354) (379) (402) (410) (418) (424) (428) (439) (457) (459) (479) (480) (482) (487) (488) (489) (491) (495) (500) (504) (506) (507) (508) (524) (527) (530) (531) (540) (545) (559) (561) (562) (565) (566) (567) (568) (569) (579) (605) (612) (618) (619) (620) (623) (626) (628) (629) (634) (636) (654) (659) (660) (682) (687) (690) (708) (709) (710) (733) (743)
6) Smooth muscle cell: (47) (64) (150) (153) (264) (293) (306) (325) (328) (410) (417) (418) (424) (457) (459) (479) (480) (482) (487) (491) (506) (566) (568) (618) (619) (622) (634) (708)
7) Endothelial cell: (54) (133) (217) (277) (335) (346) (353) (379) (380) (394) (408) (460) (462) (468) (479) (488) (489) (491) (512) (523) (531) (567) (569) (660) (733)
8) Adhesion molecule: (217) (314) (335) (379) (380) (599) (612) (636) (733)
9) T-cell: (379) (445) (636)
10) Cytokines and the receptors: (222) (229) (257) (333) (358) (367) (380) (402) (445) (480) (482) (527) (530) (531) (567) (634) (659)
11) Matrix metalloproteinase: (480) (482) (495) (536) (569) (605) (610) (618) (619) (626) (629) (630) (641) (659) (708) (712)
12) Collagen fiber: (293) (306) (325) (410) (443) (480) (482) (487) (491) (506) (509) (569) (594) (620) (676) (703) (708)
13) Elastin: (252) (317) (703)
14) Calcium accumulation: (203) (509) (520) (521) (622) (708) (713) (715) (720)
15) Lipid accumulation: (45) (49) (59) (60) (85) (86) (103) (106) (121) (133) (150) (164) (171) (173) (179) (208) (221) (226) (230) (285) (290) (293) (306) (307) (311) (325) (376) (452) (457) (487) (491) (496) (504) (506) (527) (531) (566) (708) (733) (738)
16) Modified LDL: (385)
17) Oxidized LDL: (92) (103) (107) (140) (148) (150) (183) (188) (290) (331) (364) (380) (392) (418) (433) (440) (442) (447) (449) (453) (454) (457) (462) (465) (467) (488) (500) (504) (524) (527) (531) (568) (619) (670) (708) (709) (733) (738)
18) Others: (18) (24) (89) (96) (162) (165) (216) (285) (289) (302) (303) (308) (321) (345) (489) (505) (634)


I-2. In vitro study

1) Smooth muscle cells: (229) (389) (390) (443) (459) (482) (519) (525) (627)
2) Macrophage: (44) (82) (84) (291) (331) (360) (442) (459) (480) (503) (637)
3) Endothelial cells: (433)
4) Other cells: (530)


I-3. Vasoreactivity

1) Vasorelaxation: (21) (93) (110) (119) (125) (131) (162) (189) (192) (204) (224) (227) (248) (263) (277) (279) (280) (283) (313) (318) (321) (324) (340) (346) (353) (355) (418) (419) (422) (469) (473) (485) (514) (522) (523) (547) (548) (566) (574) (575) (589) (595) (597) (656) (744) (745)
2) Nitric oxide: (224) (258) (263) (332) (340) (353) (408) (433) (479) (522) (523) (533) (544) (547) (548) (614) (616) (617) (621) (624) (656)
3) Vasoconstraction and Spasm: (304) (313) (320) (332) (424) (485) (577) (589) (595) (613) (656) (679) (700) (704) (733)
4) Endothelin: (416) (419) (420) (427) (433) (479) (512) (608) (613) (624)
5) Endothelial cells: (318) (379) (394) (408) (469) (479) (522) (523) (533) (547) (548) (575) (577) (589) (595) (597) (621) (624) (656)

I-4. Thrombogenesis

1) Platelet: (113) (125) (136) (142) (143) (145) (187) (220) (225) (242) (278) (439) (449) (489) (719)
2) Thrombosis: (143) (145) (271) (378) (386) (679) (733)
3) Arachidonic metabolism: (105) (115) (144) (259) (573)

I-5. Lesions in the other arteries

1) Intracranial arteries: (189) (313) (437) (486) (544) (595) (727) (733) (737) (741) (746)
2) Carotid artery: (324) (332) (408) (425) (437) (531) (542) (725) (733)
3) Other arteries: (95) (131) (170) (202) (497) (528) (727) (740) (749)

I-6. Oxidative stress:

1) Oxidative stress: (92) (103) (107) (140) (150) (183) (185) (188) (290) (331) (364) (380) (382) (392) (418) (422) (433) (440) (442) (447) (449) (453) (454) (457) (462) (465) (467) (488) (489) (493) (500) (501) (504) (511) (513) (522) (524) (527) (545) (546) (566) (571) (575) (592) (608) (615) (619) (636) (670) (710)
2) Antioxidants: (79) (81) (82) (134) (142) (148) (166) (188) (190) (205) (207) (211) (228) (234) (294) (322) (348) (355) (359) (370) (383) (388) (392) (398) (402) (423) (434) (436) (440) (447) (451) (454) (458) (467) (483) (493) (501) (511) (514) (517) (519) (522) (533) (556) (562) (571) (575) (592) (619) (656)

I-7. Inflammation

(557) (565) (579) (598) (600) (605) (615) (659) (672) (683) (687) (688) (690) (733)

I-8. Imaging

1) Ultrasound including IVUS: (458) (601) (607) (644) (653) (664) (666) (670) (680) (699) (712) (733) (740)
2) Positron emission tomography (PET): (472) (559) (593) (598) (670) (680) (705) (709) (733)
3) Optical Coherence Tomography (OCT),Computed Tomography (CT) and Single Photon Emission Computed Tomography (SPECT): (559) (616) (621) (625) (628) (656) (658) (681) (687) (715) (747)
4) Magnetic resonance (MR) imaging: (405) (466) (481) (518) (529) (541) (586) (588) (590) (594) (602) (606) (610) (611) (656) (662) (678) (685) (691) (694) (728) (741)
5) Angiography: (381) (528) (681) (704)
6) Autoradiographic imaging: (273) (276) (349) (599) (625) (670)
7) Others: (404) (512) (636) (639) (641) (642) (645) (648) (657) (676) (684) (701) (706) (707) (716) (730) (738) (748)

I-9. Others

1) Blood pressure: (126) (169) (230) (243) (566)
2) Arterial media: (317) (325) (328) (617)
3) b -VLDL, IDL and chylomicron remnant: (361) (382) (387) (389) (428) (525) (542)
4) Lipoprotein receptors: (354) (360) (417) (428) (484) (525) (654) (710) (743)
5) Angiotensin: (163) (168) (240) (244) (336) (437) (455) (460) (469) (548) (577) (614)
6) Apoptosis: (432) (442) (482) (564) (619) (620) (623)
7) Vitronectin: (307) (373)
8) Social stress and enviroment: (509) (558) (572) (591) (615) (707)
9) Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): (583) (592) (600) (623) (625)
10) RAGE, AGE, Glycation: (590) (732)
11) Pulse wave velocity: (597) (703) (749)
12) Others: (19) (121) (135) (176) (223) (321) (347) (404) (431) (461) (489) (505) (507) (520) (522) (528) (546) (572) (590) (608) (612) (623) (688) (714)


II. Coronary heart disease

II-1. Coronary lesion:

(2) (16) (61) (84) (96) (235) (243) (289) (293) (318) (325) (356) (367) (382) (383) (420) (441) (444) (472) (485) (487) (507) (515) (528) (540) (544) (560) (561) (564) (569) (589) (608) (609) (618) (619) (620) (626) (663) (679) (693) (696) (700) (704) (708) (715) (719) (727) (729) (733)

2) Arterial Remodeling: (277) (466) (564) (574) (590) (619) (733)

II-2. Cardiac function

1) Electrocardiogram, Echo: (154) (663) (679) (704) (733)
2) Coronary blood flow: (84) (154) (394) (420) (422) (427) (472) (566)
3) Other studies: (744) (745)


II-3. Myocardial lesion and ACS

(61) (96) (243) (356) (378) (383) (538) (540) (560) (561) (580) (626) (663) (679) (690) (700) (704) (719) (733)




III. Intervaention of atherosclerosis

III-1. HMG-CoA reductase inhibitor

1) Pravastatin: (90) (124) (156) (175) (214) (283) (325) (385) (423) (436) (441) (482) (487) (490) (506) (578) (583) (677) (734)
2) Simvastatin: (205) (323) (388) (468) (478) (569) (677) (734)
3) Fluvastatin: (410) (482) (487) (506) (511) (547) (551) (592)
4) Cerivastatin: (390) (444) (476) (480) (495) (677)
5) Others: (464) (536) (581) (610) (621) (677) (682) (692) (699) (703) (723) (734)

III-2. Combination treatment:

(124) (156) (441) (490) (578) (610) (616) (617) (621) (624) (692) (734)

III-3. Bile acid sequestrant

1) Cholestyramine: (70) (124) (156)
2) Partial ileal bypass: (17) (20) (67)

III-4.Antioxidants

1) Probucol: (79) (81) (82) (134) (142) (148) (166) (188) (201) (207) (228) (294) (348) (355) (380) (384) (398) (412) (423) (436) (440) (447) (454) (458) (483) (501) (511) (519) (539) (566) (572) (593) (594) (682) (734)
2) Vitamin E: (234) (294) (322) (351) (355) (380) (447) (467) (483) (493) (514) (519) (539) (551) (556) (592)
3) Others: (190) (211) (359) (372) (388) (392) (398) (434) (440) (447) (451) (483) (517) (519) (533) (534) (539) (551) (556) (562) (571) (636) (656)

III-5. Other compounds

1) ACAT inhibitor: (330) (357) (587) (610)
2) Antihypertensive drug
2-1) Calcium antagonist: (30) (40) (66) (68) (158) (320) (340) (396) (423) (426) (455)
2-2) ACE inhibitor: (163) (168) (240) (244) (320) (336) (438) (449) (614) (616)
2-3) Angiotensin II receptor antagonist: (438) (490) (508) (578) (616) (617) (621) (624)
2-4) b -blocker: (163) (533)
3) Anti-inflamatory drugs: (116) (256)
4) Fibrats: (391)
5) Thiazolidinedione: (440) (567)
6) Antiallergic drug: (445)
7) Others: (185) (319) (320) (372) (501) (530) (619) (624) (659) (692) (712) (722) (740)

III-6. Gene therapy:

(437) (568) (640) (683) (721) (722)

III-7. Angioplasty:

(203) (246) (272) (384) (425) (466) (488) (574) (584) (647) (674) (687) (698) (722)

III-8. apoA and HDL

(652) (671)

III-9. Others

1) w3-fatty acids or Fish oil: (109) (113) (125) (152) (414) (423) (566) (734)
2) Unsaturated fatty acides: (322)
3) Colony stimulating factor: (184) (233) (260) (288) (291) (402) (442) (446) (584) (734)
4) Apo E: (251) (350)
5) Dextransulfate: (298)
6) Heparin: (149) (227) (399)
7) Plasmapheresis: (58) (147) (213) (249)
8) Hormon replacement therapy: (496) (544) (589) (595) (613)
9) Others: (24) (27) (127) (128) (268) (515) (543) (596) (603) (622) (632) (656) (672) (675)


IV. Lipid Metabolism

IV-1. Lipoprotein receptors

  1) LDL receptor
1-1) Fibroblast: (4) (7) (25) (57) (400) (450) (668) (733)
1-2) Hepatocyte (liver): (8) (9) (38) (52) (56) (69) (123) (191) (407) (415)
1-3) Other cells: (8) (11) (28) (80) (300) (516) (525)
1-4) Processing of the protein: (25) (57) (733)
1-5) Monoclonal antibody and Imaging: (34) (38)

2) VLDL receptor: (287) (339) (354) (374) (525) (654) (710) (733)
3) b-VLDL receptor: (28) (262) (525)
4) Scavenger receptor: (28) (484) (488)
5) LRP: (174) (296) (334)

IV-2. Lipoprotein metabolism

1) VLDL: (14) (26) (99) (132) (161) (186) (196) (206) (292) (297) (316) (339) (411) (477) (499) (532) (568) (575) (633) (654) (710) (733)
2) LDL: (4) (7) (8) (12) (15) (37) (54) (84) (120) (151) (186) (196) (212) (262) (289) (461) (568) (575) (733)
3) HDL: (118) (157) (215) (391) (412) (461) (545) (660)
4) Chylomicron: (13) (52) (160) (195) (197) (236) (305) (334) (338) (344) (360) (361) (389)
5) b-VLDL: (54) (112) (209) (262) (382) (428) (525)
6) Lp(a): (270) (474) (505) (609) (710)
7) Receptor-independent LDL metabolism: (22) (77) (100) (545)
8) Cholesterol biosynthesis: (23) (343) (477)
9) Cholesterol-7a-hydroxylase: (343) (362) (407) (477) (510)
10) CETP: (46) (412) (636)
11) LCAT: (430) (456) (461)
12) Steroidgenesis in adrenal: (42)
13) HTGL(HLP), LPL, EL: (161) (191) (339) (463) (477) (549) (568) (633) (660) (710) (726)
14) Bile acids: (362) (510) (549)
15) Others: (10) (24) (62) (75) (77) (88) (89) (114) (130) (141) (166) (167) (172) (177) (362) (395) (429) (510) (575) (695)

IV-3. Modified lipoprotein

1) LDL: (266) (294) (312) (331) (413) (471) (488) (493) (511)
2) HDL: (267) (545)
3) Others: (22) (77) (91) (155) (281) (406)

IV-4. Apolipoproteins

1) Apo A: (118) (157) (199) (215) (238) (326) (430) (456) (545)
2) Apo B: (75) (99) (151) (177) (186) (232) (292) (299) (327) (363) (365)
3) Apo C: (10) (35)
4) Apo E: (10) (35) (87) (130) (198) (238) (285) (339) (575) (710)
5) Others: (10) (88)


IV-5. In vitro study

1) Smooth muscle cells: (55) (112) (193) (300) (389) (525)
2) Macrophages: (53) (91) (132) (198) (206) (209) (239) (331) (360) (710)
3) Fibroblasts: (74) (112) (198)
4) Hepatocytes: (327)
5) Others: (215)

IV-6. Others

(73) (108) (129) (137) (155) (271) (483) (502) (548) (553) (699)




V. Lipid metabolism-improving compound

V-1. HMG-CoA reductase inhibitors

1) Compactin: (6) (676)
2) Pravastatin: (50) (90) (122) (123) (124) (156) (166) (214) (245) (250) (284) (305) (316) (385) (409) (415) (441) (470) (573) (655) (677) (734)
3) Simvastatin: (205) (374) (569)
4) Lovastatin: (56) (677)
5) Fluvastatin: (297) (329) (411) (470) (511) (547)
6) Cerivastatin: (444)
7) Atorvastatin: (502) (610) (682)
7) Others: (281) (464) (536) (549) (677) (713) (735)

V-2. Combination treatment:

(123) (124) (156) (166) (245) (441) (610) (734)

V-3. Bile acid sequestrant

1) Cholestyramine: (31) (33) (71) (123) (124) (156) (166) (245) (305)
2) Other compounds: (407)
3) Partial ileal bypass: (17) (20) (33) (37) (67) (120) (196) (713)

V-4. Antioxidant:

(36) (111) (266) (294) (312) (412) (441) (470)

V-5. Other compounds

1) ACE inhibitor: (315)
2) ACAT inhibitor: (330) (369) (610)
3) MTP inhibitor: (435) (499) (734)
4) Thiazolidinedione: (375) (395) (411) (441)
5) Fibrate: (391) (502) (573) (713)
6) Others: (32) (71) (72) (98) (127) (128) (268) (463) (502) (532) (554) (573) (713)

V-6. Gene therapy

1) LDL receptor expression: (101) (102) (178) (180) (182) (218) (219) (249) (269) (309) (342) (368) (448) (450) (492) (535) (552) (555) (660) (668) (721) (731) (734)
2) ApoB edittimg: (363) (365)
3) LPL over expression: (568) (734)

V-7. Hepatocellular transplantation:

(181) (261) (370) (403) (650) (655) (721)

V-8. Others

1) Colony stimulating factor: (172) (200) (233) (260) (287) (288) (291) (295) (374) (734)
2) w3-fatty acids or Fish oil: (109) (113) (414) (713) (734)
3) Unsaturated fatty acids: (199)
4) Estradiol: (161) (191) (496)
5) Apo E: (130) (139) (167) (575)
6) Plasmapheresis: (29) (58) (65) (97) (213) (249) (281)
7) Others: (286) (603) (632) (713) (734)



VI. Genome analyses, Transgenic WHHL rabbits, Gene therapy, and Regenerative therapy

VI-1. Genome analyses:

(702) (714) (724) (725) (733)

VI-2. Transgenic WHHL rabbits:

(430) (456) (461) (474) (505) (521) (550) (568) (609) (733)

VI-3. Gene therapy

1) LDL receptor expression: (101) (102) (178) (180) (182) (218) (219) (249) (269) (309) (342) (368) (448) (450) (492) (535) (555) (668) (721) (731) (733)
2) ApoB edittimg: (363) (365)
3) Angiogenesis: (528) (537) (590) (640) (722) (733)
4) Others: (408) (437) (722)

VI-4. Gene transduction

1) Cyclooxhgenase-1 (COX-1): (574)

VI-5. Regenerative therapy:

(650) (655)



VII. Metabolic syndrome, Insulin Resistance, and Diabetese

(194) (315) (375) (395) (411) (441) (494) (498) (550) (572) (590) (633) (661) (690) (696) (713) (744) (745)



VIII. Other studies

VIII-1. Development of WHHL/WHHLMI rabbirs:

(1) (2) (3) (39) (235) (538) (540) (553) (560) (561) (580) (626) (630) (631) (669) (733) (739) (742)

VIII-2. Heterozygous WHHL rabbits:

(7) (117) (123) (158) (274) (275) (286) (289) (296) (305) (318) (323) (333) (337) (364) (366) (385) (407) (411) (415) (422) (436) (461) (463) (476) (502) (504) (632)

VIII-3. Angiogenesis:

(393) (528) (537) (590) (640)

VIII-4. Blood pressure:

(2) (51) (94) (126) (169) (254) (255) (319) (375) (733)

VIII-5. Aortic valve disease

(581) (717) (733)

VIII-6. Aging:

(194) (216) (248) (274) (275) (276) (280) (282) (293) (306) (313) (477) (553) (560)

VIII-7. Social stress and environment

(509) (558) (572) (707)

VIII-8. Urinary function:

(284) (638) (668) (733)

VIII-9. Metablomics, Lipidomics, and Blood Markers:

(651) (695) (711) (713) (718) (720) (729) (733) (735)

VIII-10. Pulse wave velocity:

(597) (703) (749)

VIII-11. Others

1) Obesity and adipocyte: (441) (550) (713) (733)
2) Hematologic profile: (242) (278)
3) Xanthoma: (1) (2) (3) (76) (90) (582) (733)
4) Osteonecrosis: (5) (733)
5) Keratopathy: (89) (104) (585)
6) Ischemic changes in pancreas: (95)
7) Reproductive ability: (2) (41) (78) (210) (278) (310) (366)
8) Cranial nerve disease : (526) (736)
10) Others: (2) (43) (48) (138) (159) (210) (231) (237) (241) (253) (301) (337) (352) (369) (371) (475) (515) (546) (548) (563) (604) (690)

IX. Review Article
1) Lipid Metabolism: (24) (27) (114) (186) (292) (423) (456) (566) (626) (630) (631) (665) (669) (677) (688) (710) (733) (734)
2) Atherosclerosis: (24) (27) (165) (346) (423) (505) (540) (561) (566) (626) (630) (631) (652) (669) (688) (709) (710) (733) (734) (742) (743)
3) Developmemt of Therapeutic Methods: (148) (256) (320) (489) (506) (543) (570) (626) (630) (631) (652) (677) (734)
4) Myocardial infarction: (540) (561) (626) (630) (631) (652) (733) (734)
5) Others: (667) (725) (733) (734) (739) (742)



  Bibliography of WHHL Rabbits